Researchers use synthetic biology approaches to test hundreds of DNA sequences for their effect on regulating gene expression. The human genome contains over 20,000 genes. However, at any given time and in a given cell, only a fraction of them are active. Researchers from EMBL Heidelberg’s Krebs Group have come up with an innovative experimental approach to understand how cells determine which genes to turn on and when.

Researchers from Heidelberg University’s Faculty of Medicine, Harvard Medical School, and the German Cancer Research Center (DKFZ) have uncovered key mechanisms underlying the proliferation of the malaria parasite Plasmodium. The molecular processes that govern the formation of infectious daughter parasites and new nuclei are essential for parasite survival and may therefore represent targets for future antimalarial therapies.

The University of Freiburg took part in this year’s Käpsele Innovation Festival with contributions from the fields of research and entrepreneurship promotion. The event focused on future-oriented topics such as Artificial Intelligence, cybersecurity and resilience, as well as on fostering dialogue and networking amongst stakeholders from the worlds of academia, business and politics.

The international research project MitoContact is dedicated to investigating how organelles within a cell communicate and interact with other cellular components. Kai Johnsson, Director at the Max Planck Institute for Medical Research, has received funding from the ERC for this project. The findings are expected to provide new insights into fundamental cellular processes and contribute to a better understanding of various diseases.

EMUNO Therapeutics: the innate immune system as a new approach to cancer treatment - 29/07/2026

Activation of macrophages: a key factor in the fight against colorectal cancer

The mobilisation of the body’s own immune system through immune checkpoint inhibitors has revolutionised cancer therapy. However, the majority of solid tumours are able to evade immune surveillance. These so-called 'cold' tumours contain too few immune cells to respond effectively to current immunotherapies. This is where the Freiburg-based biotech start-up EMUNO Therapeutics GmbH comes in.